Four serious cases of COVID, no deaths

Four serious cases of COVID, no deaths

by

A year ago we asked ourselves if an effective coronavirus vaccine could ever be developed for humans. Six months ago, we wondered if any of the vaccines in the pipeline would really work or if the 50 percent efficiency was the best we could hope for.

Today, looking at these numbers, I wonder if the pfizer and Moderna mRNA vaccines are the most important medical breakthrough since the polio vaccine.

Remember that the part of the population in Israel that is fully vaccinated is getting older strongly. According to the latest data, 80 percent of Israelis aged 60 or older both got their shots, while only 20 percent of the 16-59 demographic. The vaccine eliminated COVID deaths and eliminated severe cases of COVID among the demographics most sensitive * to the outcomes.

Salvation:

An Israeli healthcare provider who vaccinated half a million people with both doses of Pfizer vaccine says only 544 people – or 0.1% – were subsequently diagnosed with coronavirus; there were four serious cases and no people were killed.

This means that the efficiency rate stands at 93 percent, Maccabi Healthcare Services announced on Thursday after comparing the vaccinated members with a ‘diverse’ control group of non-vaccinated members …

Of the 523,000 people who were fully vaccinated, 544 were infected with COVID-19, of whom 15 needed hospitalization: eight were in a mild condition, three in a moderate condition and four in a serious condition.

If you had both shots, you have a chance of being infected about one in 1,000, a chance of one in 35,000 being sent to the hospital, and a chance of one in 130,000 to be really worrying. case. And again, this is an example that includes a large percentage of older, previously vulnerable people. The vaccine lifted the cloud of COVID over the heads of Israeli senior citizens.

So much so, in fact, that Israeli hospitals now see more patients under 60 being admitted to the hospital as a result of the disease:

A parent immunized in Israel has a stronger immune response to the coronavirus than an unimmunized person under 60, it appears. The image to the right also shows the curve of hospitalizations according to age, which begins to shift as vaccinations increase:

The obvious ripple is that this data only tells us how effective the mRNA vaccines are. The vaccines that are still in the pipeline, such as Johnson’s and Johnson’s and Novavax’s, use different ways to elicit an immune response and have not achieved 95% efficacy in clinical trials as Pfizer and Moderna have. However, Biden’s pandemic advisers yesterday published a group warning people not to hang on to the efficiency rates. It would be great if every vaccine is just as effective as Pfizer in preventing infection, but when it comes to pressure, no one cares about infection. We care about serious cases and deaths. A vaccine that did not prevent you from getting sick, but * did * prevent your symptoms from getting worse than a cough and a few days of low fever, would be a great triumph with the death toll rising to 500,000 has. The good news, Biden’s advisers say, is that every major vaccine tested so far has been 100 percent effective in preventing poor trial results.

All seven COVID-19 vaccines that have completed major efficacy trials – Pfizer, Moderna, Johnson & Johnson, Novavax, AstraZeneca, Sputnik V and Sinovac – appear to be 100% effective for serious complications. Not one person vaccinated became ill enough to require hospitalization. Not one vaccinated person died from COVID-19.

Not all infections are the same. People who are vaccinated against viruses are still sometimes infected. But thanks to an immune system fed by vaccines, the infections never get seriously ill. Vaccine efficacy rates vary only with respect to mild forms of COVID-19 disease. When it comes to the measures that really matter – hospitalizations and death – they are all functionally the same.

The reason the publication was published was to urge Americans not to stick to an mRNA vaccine if it is not available locally once you are eligible. People who follow the news about COVID already know that Pfizer and Moderna are extremely effective in preventing infection, while Johnson & Johnson’s product, at least according to the trial data, is a little less. Some will therefore be asked to pass on J&J, to wait until the mRNA products are back in stock. But it’s a bad idea, like choosing to fight without a bulletproof vest, because the model of the vest is sold out at the moment. When pressure comes pressure, any vest that stops the bullet is fine. And in the case of COVID, according to what scientists can tell so far, every ‘vest’ on the market will, or will soon, perform the task.

By the way, although Israel’s vaccination effort continues, they have recently begun to relax:

To some extent, the delivery is a simple matter that there are fewer unwanted people walking around at this point. But it also suggests that Israel has pushed the outer limits of the vaccine-skeptical section of the population. It’s easy to get people immunized quickly in the beginning if you have an effective delivery system, as everyone who has gung ho will be queuing up without needing encouragement. But they are now through the group. It’s time to start working on the fence sitters to move further towards herd immunity.

Instead of an exit question, read this story about the FDA’s relief from Moderna to include 14 doses of its vaccine in its vials instead of 10, a boost that will quickly increase supply by 20 percent. That is the good news. The bad news is that more doses in each vial have a greater risk of wasting doses, if the total stock is not used within six hours of opening. Good luck to the next doctor Gokal who is eventually fired and prosecuted for trying to do the right thing in that situation.

.Source